LifeTech Scientific Crecimiento futuro
Future controles de criterios 5/6
Se prevé un crecimiento anual de los beneficios y los ingresos de LifeTech Scientific de 29.5% y 21.5% respectivamente, mientras que el BPA crecerá en un 29.7% al año.
Información clave
29.5%
Tasa de crecimiento de los beneficios
29.7%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Medical Equipment | 39.9% |
| Tasa de crecimiento de los ingresos | 21.5% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 31 Oct 2024 |
Actualizaciones recientes sobre el crecimiento futuro
No hay actualizaciones
Recent updates
LifeTech Scientific Corporation (HKG:1302) Looks Just Right With A 29% Price Jump
Oct 02
Some Confidence Is Lacking In LifeTech Scientific Corporation's (HKG:1302) P/E
Jul 05LifeTech Scientific's (HKG:1302) Soft Earnings Are Actually Better Than They Appear
Apr 25What LifeTech Scientific Corporation's (HKG:1302) P/E Is Not Telling You
Dec 25Returns On Capital At LifeTech Scientific (HKG:1302) Have Stalled
Nov 28At HK$2.37, Is LifeTech Scientific Corporation (HKG:1302) Worth Looking At Closely?
Nov 03Investors Met With Slowing Returns on Capital At LifeTech Scientific (HKG:1302)
Aug 17Is There Now An Opportunity In LifeTech Scientific Corporation (HKG:1302)?
Jul 18Investors Met With Slowing Returns on Capital At LifeTech Scientific (HKG:1302)
May 05Here's What To Make Of LifeTech Scientific's (HKG:1302) Decelerating Rates Of Return
Oct 14There's Been No Shortage Of Growth Recently For LifeTech Scientific's (HKG:1302) Returns On Capital
Jul 15Does LifeTech Scientific (HKG:1302) Deserve A Spot On Your Watchlist?
Jun 30A Look At The Fair Value Of LifeTech Scientific Corporation (HKG:1302)
Jun 15Returns At LifeTech Scientific (HKG:1302) Are On The Way Up
Apr 03Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock
Mar 15Is LifeTech Scientific Corporation (HKG:1302) Potentially Undervalued?
Jan 22Some Investors May Be Worried About LifeTech Scientific's (HKG:1302) Returns On Capital
Dec 19Here's Why I Think LifeTech Scientific (HKG:1302) Might Deserve Your Attention Today
Dec 06Is LifeTech Scientific (HKG:1302) A Risky Investment?
Nov 20An Intrinsic Calculation For LifeTech Scientific Corporation (HKG:1302) Suggests It's 34% Undervalued
Oct 12The Returns On Capital At LifeTech Scientific (HKG:1302) Don't Inspire Confidence
Sep 13Should You Be Adding LifeTech Scientific (HKG:1302) To Your Watchlist Today?
Aug 28What Is LifeTech Scientific Corporation's (HKG:1302) Share Price Doing?
Aug 13LifeTech Scientific's (HKG:1302) Returns On Capital Not Reflecting Well On The Business
Jun 08Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock
May 26Should You Investigate LifeTech Scientific Corporation (HKG:1302) At HK$4.14?
May 11LifeTech Scientific (HKG:1302) Could Easily Take On More Debt
Mar 31Shareholders Are Thrilled That The LifeTech Scientific (HKG:1302) Share Price Increased 274%
Feb 21Do Insiders Own Lots Of Shares In LifeTech Scientific Corporation (HKG:1302)?
Jan 26Does LifeTech Scientific's (HKG:1302) Statutory Profit Adequately Reflect Its Underlying Profit?
Dec 13
Are Strong Financial Prospects The Force That Is Driving The Momentum In LifeTech Scientific Corporation's HKG:1302) Stock?
Nov 25Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2025 | 1,774 | 399 | N/A | 406 | 1 |
| 12/31/2024 | 1,474 | 328 | N/A | 325 | 1 |
| 6/30/2024 | 1,281 | 249 | -58 | 298 | N/A |
| 3/31/2024 | 1,274 | 256 | 34 | 358 | N/A |
| 12/31/2023 | 1,267 | 263 | 125 | 418 | N/A |
| 9/30/2023 | 1,224 | 297 | 84 | 393 | N/A |
| 6/30/2023 | 1,182 | 331 | 43 | 367 | N/A |
| 3/31/2023 | 1,139 | 328 | 48 | 378 | N/A |
| 12/31/2022 | 1,097 | 325 | 53 | 388 | N/A |
| 9/30/2022 | 1,058 | 314 | 86 | 437 | N/A |
| 6/30/2022 | 1,019 | 303 | 119 | 486 | N/A |
| 3/31/2022 | 972 | 298 | 108 | 464 | N/A |
| 12/31/2021 | 925 | 292 | 98 | 441 | N/A |
| 9/30/2021 | 878 | 307 | 147 | 436 | N/A |
| 6/30/2021 | 830 | 322 | 196 | 432 | N/A |
| 3/31/2021 | 736 | 269 | 188 | 385 | N/A |
| 12/31/2020 | 642 | 216 | 180 | 339 | N/A |
| 9/30/2020 | 638 | 176 | 154 | 303 | N/A |
| 6/30/2020 | 633 | 136 | 128 | 268 | N/A |
| 3/31/2020 | 651 | 132 | 144 | 271 | N/A |
| 12/31/2019 | 669 | 129 | 161 | 275 | N/A |
| 9/30/2019 | 644 | 138 | 146 | 252 | N/A |
| 6/30/2019 | 618 | 146 | 132 | 229 | N/A |
| 3/31/2019 | 588 | 134 | 101 | 206 | N/A |
| 12/31/2018 | 557 | 121 | 70 | 182 | N/A |
| 9/30/2018 | 518 | 134 | 71 | 190 | N/A |
| 6/30/2018 | 480 | 147 | 72 | 199 | N/A |
| 3/31/2018 | 445 | 155 | N/A | 177 | N/A |
| 12/31/2017 | 409 | 163 | N/A | 155 | N/A |
| 9/30/2017 | 391 | 171 | N/A | 146 | N/A |
| 6/30/2017 | 373 | 178 | N/A | 136 | N/A |
| 3/31/2017 | 363 | 162 | N/A | 132 | N/A |
| 12/31/2016 | 353 | 146 | N/A | 127 | N/A |
| 9/30/2016 | 336 | 201 | N/A | 121 | N/A |
| 6/30/2016 | 319 | 256 | N/A | 115 | N/A |
| 3/31/2016 | 315 | 129 | N/A | 130 | N/A |
| 12/31/2015 | 312 | 2 | N/A | 144 | N/A |
| 9/30/2015 | 304 | -41 | N/A | 113 | N/A |
| 6/30/2015 | 296 | -84 | N/A | 81 | N/A |
| 3/31/2015 | 289 | -83 | N/A | 50 | N/A |
| 12/31/2014 | 283 | -81 | N/A | 20 | N/A |
| 9/30/2014 | 280 | -151 | N/A | N/A | N/A |
| 6/30/2014 | 258 | -209 | N/A | 6 | N/A |
| 3/31/2014 | 248 | -89 | N/A | N/A | N/A |
| 12/31/2013 | 231 | -66 | N/A | 35 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (29.5% al año) de 1302 es superior a la tasa de ahorro (2.3%).
Beneficios vs. Mercado: Se prevé que los beneficios (29.5% al año) de 1302 crezcan más rápidamente que el mercado Hong Kong (11.6% al año).
Beneficios de alto crecimiento: Se espera que los beneficios de 1302 crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (21.5% al año) de 1302 crezcan más rápidamente que los del mercado Hong Kong (7.8% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (21.5% al año) de 1302 crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 1302 se prevé que sea elevada dentro de 3 años.